Actively targeted cetuximab conjugated γ-poly(glutamic acid)-docetaxel nanomedicines for epidermal growth factor receptor over expressing colon cancer cells

Journal of Biomedical Nanotechnology

Volumn 10, Issue 8, 2014, Pages 1416-1428

  Maya, S ^a   Sarmento, Bruno ^b,c,d   Lakshmanan, Vinoth Kumar ^a   Menon, Deepthy ^a   Jayakumar, R ^a  

^a AMRITA INSTITUTE OF MEDICAL SCIENCES   (India)

^b UNIVERSITY OF PORTO   (Portugal)

^c UNIVERSITY INSTITUTE OF HEALTH SCIENCES IUCS   (Portugal)

^d INEB INSTITUTO DE ENGENHARIA BIOMÉDICA   (Portugal)

Author keywords

Cetuximab; Colon cancer; Docetaxel; Epidermal growth factor receptor; Poly( glutamic acid) nanoparticles; Targeted nanomedicines

Indexed keywords

AMINO ACIDS; CELL DEATH; MAGNESIUM PRINTING PLATES; NANOPARTICLES;

CETUXIMAB; COLON CANCER; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTORS; GLUTAMIC ACID; NANOMEDICINES;

DISEASES;

CETUXIMAB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; NANOPARTICLE; POLYGLUTAMIC ACID;

ANIMAL CELL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BLOOD COMPATIBILITY; CANCER CELL LINE; CELL DEATH; CELL VIABILITY; CELLULAR DISTRIBUTION; COLON CANCER; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG CONJUGATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG RELEASE; DRUG UPTAKE; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; GENE OVEREXPRESSION; HYDROPHILICITY; HYDROPHOBICITY; INFRARED SPECTROSCOPY; M PHASE CELL CYCLE CHECKPOINT; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; MTT ASSAY; NANOENCAPSULATION; NANOMEDICINE; NEAR INFRARED SPECTROSCOPY; NONHUMAN; PARTICLE SIZE; SCANNING ELECTRON MICROSCOPY; ZETA POTENTIAL;

ANIMALS; ANNEXINS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; CARBOCYANINES; CELL CYCLE; CELL DEATH; COLONIC NEOPLASMS; DRUG CARRIERS; HEMOLYSIS; HT29 CELLS; HUMANS; MICE; NANOMEDICINE; NANOPARTICLES; POLYGLUTAMIC ACID; RECEPTOR, EPIDERMAL GROWTH FACTOR; TAXOIDS; TISSUE DISTRIBUTION;

EID: 84899683740     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2014.1841     Document Type: Article

References (29)

1. V. P. Torchilin, Passive and active drug targeting: Drug delivery to tumors as an example. Handb. Exp. Pharmacol. 197, 3 (2010).
2. S. R. Benhabbour, J. C. Luft, D. Kim, A. Jain, S. Wadhwa, M. C. Parrott, R. Liu, J. M. DeSimone, and R. J. Mumpe, In vitro and in vivo assessment of targeting lipid-based nanoparticles to the epidermal growth factor-receptor (EGFR) using a novel Heptameric ZEGFR domain. J. Control. Release 158, 63 (2012).
3. C. Gialeli, D. Kletsas, D. Mavroudis, H. P. Kalofonos, G. N. Tzanakakis, and N. K. Karamanos, Targeting epidermal growth factor receptor in solid tumors: critical evaluation of the biological importance of therapeutic monoclonal antibodies. Curr. Med. Chem. 16, 3797 (2009).
4. J. Mendelsohn, The epidermal growth factor receptor as a target for cancer therapy. Endocr. Relat. Cancer 8, 3 (2001).
5. D. S. Salomon, R. Brandt, F. Ciardiello, and N. Normanno, Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 19, 183 (1995).
6. R. Bianco, T. Gelardi, V. Damiano, F. Ciardiello, and G. Tortora, Rational bases for the development of EGFR inhibitors for cancer treatment. Int. J. Biochem. Cell Biol. 39, 1416 (2007).
7. W. L. Yip, A. Weyergang, K. Berg, H. H. Tonnesen, and P. K. Selbo, Targeted delivery and enhanced cytotoxicity of cetuximab-saporin by photochemical internalization in EGFR-positive cancer cells. Mol. Pharm. 4, 241 (2007).
8. X. D. Yang, X. C. Jia, J. R. Corvalan, P. Wang, C. G. Davis, and A. Jakobovits, Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res. 59, 1236 (1999).
9. H. E. Jones, L. Goddard, J. M. Gee, S. Hiscox, M. Rubini, D. Barrow, J. M. Knowlden, S. Williams, A. E. Wakeling, and R. I. Nicholson, Insulin like growth factor-1 receptor signaling and acquired ressistance to gefitinib (ZD 1839; Iressa) in human breast cancer and prostate cancer cells. Endocr. Relat. Cancer 11,793 (2004).
10. M. H. Cohen, J. R. Johnson, Y. F. Chen, R. Sridhara, and R. Pazdur, FDA drug approval summary: Erlotinib (Tarceva (R)) tablets. Oncologist 10, 461 (2005).
11. H. A. Burris, Dual kinase inhibition in the treatment of breast cancer: Initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist 9, 10 (2004).
12. M. L. Jaramillo, Z. Leon, S. Grothe, B. Paul-Roc, A. Abulrob, and M. O. McCourt, Effect of the anti-receptor ligand-blocking 225 monoclonal antibody on EGF receptor endocytosis and sorting. Exp. Cell Res. 312, 2778 (2006).
13. I. Y. Kim, Y. S. Kang, D. S. Lee, H. J. Park, E. K. Choi, Y. K. Oh, H. J. Son, and J. S. Kim, Antitumor activity of EGFR targeted pH-sensitive immunoliposomes encapsulating gemcitabine in A549 xenograft nude mice. J. Control. Release 140, 55 (2009).
14. E. Portnoy, L. Shimon, L. Philip, D. Dganit, and M. Shlomo, Cetuximab-labeled liposomes containing near-infrared probe for in vivo imaging. Nanomed: Nanotechnol. Biol. Med. 7, 480 (2011).
15. H. Gong, J. Kovar, G. Little, H. Chen, and D. M. Olive, In vivo imaging of xenograft tumors using an epidermal growth factor receptor-specific affibody molecule labeled with a near-infrared fluorophore. Neoplasia 12, 139 (2010).
16. C. Li, Poly-(L-glutamic acid)-anticancer drug conjugates. Adv. Drug Deliv. Rev. 54, 695 (2001).
17. S. Wang, X. Cao, M. Shen, R. Guo, I. IBányai, and X. Shi, Fabrication and morphology control of electrospun poly (γ-glutamic acid) nanofibers for biomedical applications. Colloids Sur. 89, 254 (2012).
18. T. Yoshikawa, N. Okada, A. Oda, K. Matsuo, K. Matsuo, H. Kayamuro, Y. Ishii, T. Yoshinaga, T. Akagi, M. Akashi, and S. Nakagawa, Nanoparticles built by self-assembly of amphiphilic PGA can deliver antigens to antigen-presenting cells with high efficiency: A new tumor-vaccine carrier for eliciting effector T cells. Vaccine 26, 1303 (2008).
19. T. Akagi, T. Kaneko, T. Kida, and M. Akashi, Preparation and characterization of biodegradable nanoparticles based on poly(γ-glutamic acid) with l-phenylalanine as a protein carrier. J. Control Release 108, 226 (2005).
20. P. Shu-Fen, T. T. Michael, H. Yi-Cheng, W. Ming-Cheng, L. Zi-Xian, and S. Hsing-Wen, Mechanisms of cellular uptake and intracellular trafficking with chitosan/DNA/poly(γ-glutamic acid) complexes as a gene delivery vector. Biomaterials 32, 239 (2011).
21. V. G. Deepagan, B. Sarmento, D. Menon, A. Nascimento, J. Aswathy, S. Maya, K. Manzoor, S. V. Nair, and R. Jayakumar, In vitro targeted imaging and delivery of camptothecin using cetuximab conjugated multifunctional PLGA-ZnS nanoparticles. Nanomedicine 7, 507 (2012).
22. S. Maya, G. K. Lekshmi, B. Sarmento, R. N. Sanoj, D. Menon, S. V. Nair, and R. Jayakumar, Cetuximab conjugated O-carboxymethyl chitosan nanoparticles for targeting EGFR overexpressing cancer cells. Carbohydr. Polym. 93, 661 (2013).
23. Y. Luo, Y. Ling, W. Guo, J. Pang, Liu W, Fang Y, X. Wen, K. Wei, and X. Gao, Docetaxel loaded oleic acid-coated hydroxyapatite nanoparticles enhance the docetaxel-induced apoptosis through activation of caspase-2 in androgen independent prostate cancer cells. J. Control. Release 147, 278 (2010).
24. S. Maya, S. Indulekha, V. Sukhithasri, K. T. Smitha, S. V. Nair, R. Jayakumar, and Raja Biswas, Efficacy of tetracycline encapsulated O-carboxymethyl chitosan nanoparticles against intracellular infections of Staphylococcus aureus. Int. J. Biol. Macromol. 51, 392 (2012).
25. A. Anitha, K. P. Chennazhi, S. V. Nair, and R. Jayakumar, 5-Flourouracil Loaded N, O-carboxymethyl chitosan nanoparticles as an anticancer nanomedicine for breast cancer. J. Biomedical Nanotechnol. 8, 1 (2012).
26. M. Valodkar, R. N. Jadeja, M. C. Thounaojam, R. V. Devkar, and S. Thakore, In vitro toxicity study of plant latex capped silver nanoparticles in human lung carcinoma cells. Mat. Sci. Eng. C 31, 1723 (2011).
27. C. Zheng, M. Zheng, P. Gong, D. Jia, P. Zhang, B. Shi, Z. Sheng, Y. Ma, and L. Cai, Indocyanine green-loaded biodegradable tumor targeting nanoprobes for in vitro and in vivo imaging. Biomaterials 33, 5603 (2012).
28. F. H. P. Ferguson, J. Koropatnick, R. Krull, and A. Margaritis, Characterization and in vitro cytotoxicity of doxorubicin-loaded γ-polyglutamic acid-chitosan composite nanoparticles. Biochem. Eng. J. 75, 72 (2013).
29. V. Saxena, M. Sadoqi, and J. Shao, Polymeric nanoparticulate delivery system for Indocyanine green: Biodistribution in healthy mice. Int. J. Pharm. 308, 200 (2006).